Allergic manifestations and cutaneous histamine responses in patients with McCune Albright syndrome

World Allergy Organization Journal

Scott A Sands¹  Angela L Turpin¹  Jill D Jacobson¹ 

[1] Section of Endocrinology, Children’s Mercy Hospital, University of Missouri-Kansas City, School of Medicine, 2401 Gillham Road, Kansas, MO 64108, USA

关键词: Anaphylaxis;    Atopy;    Wheal and flare;    Histamine responsiveness;    McCune Albright syndrome;   

Others  :  804077
DOI  :  10.1186/1939-4551-6-9

 received in 2012-09-20, accepted in 2013-04-16,  发布年份 2013

【 摘 要 】

Background

McCune Albright syndrome (MAS) is a rare disorder characterized by precocious puberty, café-au-lait spots, and fibrous dysplasia. Its cause is an activating mutation in the GNAS gene, encoding a subunit of the stimulatory G protein, G_salpha (G_sα). The action of any mediator that signals via G_sα and cyclic AMP can be up regulated in MAS. We had observed gastritis, gastroesophageal reflux, and anaphylaxis in McCune Albright patients.

Objective

As histamine is known to signal via histamine 1 (H1) and histamine 2 (H2) receptors, which couple with stimulatory G proteins, we attempted to mechanistically link histamine responsiveness to the activating GNAS mutation. We hypothesized that responsiveness to histamine skin testing would differ between MAS patients and healthy controls.

Patients and methods

After obtaining informed consent, we performed a systematic review of histamine responsiveness and allergic manifestations in 11 MAS patients and 11 sex-matched, Tanner-stage matched controls. We performed skin prick testing, quantifying the orthogonal diameters of wheals and erythema. We also quantitated G protein mRNA expression.

Results

The peak wheal and flare responses to histamine were significantly higher in MAS patients compared to controls.

Conclusions

This study suggests that MAS patients may be at risk for exaggerated histamine responsiveness compared to unaffected controls.

【 授权许可】

   
2013 Jacobson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Albright F, Butler A, Hampton A, Smith P: Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. Report of five cases. N Engl J Med 1937, 216:727-746.
• [2]Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM: Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991, 325(24):1688-1695.
• [3]Scurry MT, Bicknell JM, Fajans SS: Polyostotic Fibrous Dysplasia And Acromegaly. Arch Intern Med 1964, 114:40-45.
• [4]Lumbroso S, Paris F, Sultan C: Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome–a European Collaborative Study. J Clin Endocrinol Metab 2004, 89(5):2107-2113.
• [5]Ehrig U, Wilson DR: Fibrous dysplasia of bone and primary hyperparathyroidism. Ann Intern Med 1972, 77(2):234-238.
• [6]Shenker A, Laue L, Kosugi S, Merendino J, Minegishi T, Cutler G: A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993, 365(6447):652-654.
• [7]Danon M, Crawford JD: The McCune-Albright syndrome. Ergeb Inn Med Kinderheilkd 1987, 55:81-115.
• [8]Bajpai A, Greenway A, Zacharin M: Platelet dysfunction and increased bleeding tendency in McCune-Albright syndrome. J Pediatr 2008, 153(2):287-289.
• [9]Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, et al.: Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993, 123(4):509-518.
• [10]Roman R, Lopez P, Johnson MC, Boric MA, Gallo M, Ponce C, et al.: Sudden infant death syndrome and activating GNAS1 gene mutations. Fetal Pediatr Pathol 2007, 26(4):199-205.
• [11]Volkl TM, Dorr HG: McCune-Albright syndrome: clinical picture and natural history in children and adolescents. J Pediatr Endocrinol Metab 2006, 19(Suppl 2):551-559.
• [12]Damian M, Mary S, Martin A, Pin JP, Baneres JL: G protein activation by the leukotriene B4 receptor dimer. Evidence for an absence of trans-activation. J Biol Chem 2008, 283(30):21084-21092.
• [13]Garbarg M, Schwartz JC: Synergism between histamine H1- and H2-receptors in the cAMP response in guinea pig brain slices: effects of phorbol esters and calcium. Mol Pharmacol 1988, 33(1):38-43.
• [14]Hasko G, Shanley TP, Egnaczyk G, Nemeth ZH, Salzman AL, Vizi ES, et al.: Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism. Br J Pharmacol 1998, 125(6):1297-1303.
• [15]Nakahari T, Ito S, Yoshida H, Furuya E, Imai Y: Accumulation of cAMP evoked by acetylcholine stimulation in rat submandibular acinar cells: observation of exocytosis, fluid secretion and [Ca2+]i. Exp Physiol 2000, 85(2):159-169.
• [16]Blinowski JT: [The role of catecholamines in vasomotor rhinitis]. Pneumonol Pol 1985, 53(10):487-491.
• [17]Liu J, Jiang EK, Chang ZJ: [The effect of substance P on the content of cAMP in cultured cells of the rat anterior pituitary gland]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2003, 19(1):101-102.
• [18]Sullivan TJ, Parker KL, Eisen SA, Parker CW: Modulation of cyclic AMP in purified rat mast cells II. Studies on the relationship between intracellular cyclic AMP concentrations and histamine release. J Immunol 1975, 114(5):1480-1485.
• [19]Sullivan TJ, Parker KL, Stenson W, Parker CW: Modulation of cyclic AMP in purified rat mast cells. I. Responses to pharmacologic, metabolic, and physical stimuli. J Immunol 1975, 114(5):1473-1479.
• [20]Suh BC, Lee H, Lee IS, Kim KT: Modulation of H2 histamine receptor-mediated cAMP generation and granulocytic differentiation by extracellular nucleotides via activation of protein kinase C. J Leukoc Biol 2001, 69(1):169-176.
• [21]Gbahou F, Vincent L, Humbert-Claude M, Tardivel-Lacombe J, Chabret C, Arrang JM: Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol 2006, 147(7):744-754.
• [22]Torrent A, Moreno-Delgado D, Gomez-Ramirez J, Rodriguez-Agudo D, Rodriguez-Caso C, Sanchez-Jimenez F, et al.: H3 autoreceptors modulate histamine synthesis through calcium/calmodulin- and cAMP-dependent protein kinase pathways. Mol Pharmacol 2005, 67(1):195-203.
• [23]Chiosi E, Valente F, Naviglio S, Illiano G: “Cross talk” between protein-kinase C (PKC) and adenylate cyclase (AC) in human platelets. Ital J Biochem 1989, 38(6):407A-409A.
• [24]Bjorgo E, Solheim SA, Abrahamsen H, Baillie GS, Brown KM, Berge T, et al.: Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol 2010, 30(7):1660-1672.
• [25]Carbajal L, Biswas A, Niswander LM, Prizant H, Hammes SR: GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. Mol Endocrinol 2011, 25(6):1055-1065.
• [26]Dhanya NB, Rai R, Srinivas CR: Histamine 2 blocker potentiates the effects of histamine 1 blocker in suppressing histamine-induced wheal. Indian J Dermatol Venereol Leprol 2008, 74(5):475-477.
• [27]Moniri NH, Booth RG: Role of PKA and PKC in histamine H1 receptor-mediated activation of catecholamine neurotransmitter synthesis. Neurosci Lett 2006, 407(3):249-253.
• [28]Bakker RA, Casarosa P, Timmerman H, Smit MJ, Leurs R: Constitutively active Gq/11-coupled receptors enable signaling by co-expressed G(i/o)-coupled receptors. J Biol Chem 2004, 279(7):5152-5161.
• [29]Kalogeromitros D, Katsarou A, Armenaka M, Rigopoulos D, Zapanti M, Stratigos I: Influence of the menstrual cycle on skin-prick test reactions to histamine, morphine and allergen. Clin Exp Allergy 1995, 25(5):461-466.
• [30]Kirmaz C, Yuksel H, Mete N, Bayrak P, Baytur YB: Is the menstrual cycle affecting the skin prick test reactivity? Asian Pac J Allergy Immunol 2004, 22(4):197-203.
• [31]Morton T, Ansari M, Jacobson J: Gender differences and hormonal modulation of G protein galpha q/11 expression in lymphoid organs. Neuroendocrinology 2003, 78:147-153.
• [32]Jacobson JD, Ansari MA, Kinealy M, Muthukrishnan V: Gender specific exacerbation of murine lupus by gonadotropin-releasing hormone: Potential role of G alpha q/11. Endocrinol. 1999, 140:3429-3437.
• [33]Marshall WA JMT: Puberty. In Human Growth. Edited by Falkner FTJ. New York: Plenum Press; 1986:171–-210.
• [34]Zweiman B, Lavker RM, Presti C, Atkins PC: Comparisons of inflammatory responses in IgE-mediated and codeine-induced skin reactions. J Allergy Clin Immunol 1993, 91(4):963-965.
• [35]Sheen CH, Schleimer RP, Kulka M: Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation. Allergy 2007, 62(5):532-538.
• [36]Turkeltaub PC, Rastogi SC, Baer H, Anderson MC, Norman PS: A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose–response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol 1982, 70(5):343-352.
• [37]Petersen LJ, Mosbech H, Skov PS: Allergen-induced histamine release in intact human skin in vivo assessed by skin microdialysis technique: characterization of factors influencing histamine releasability. J Allergy Clin Immunol 1996, 97(2):672-679.
• [38]Jauregui I, Ferrer M, Montoro J, Davila I, Bartra J, del Cuvillo A, et al.: Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol 2007, 17(Suppl 2):41-52.
• [39]Lee EE, Maibach HI: Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001, 2(1):27-32.
• [40]Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L, et al.: Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000, 36(5):462-468.
• [41]Fedorowicz Z, van Zuuren EJ, Hu N: Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012., 3CD008596
• [42]Alman BA, Greel DA, Wolfe HJ: Activating mutations of Gs protein in monostotic fibrous lesions of bone. J Orthop Res 1996, 14(2):311-315.
• [43]Marie PJ, de Pollak C, Chanson P, Lomri A: Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 1997, 150(3):1059-1069.
• [44]Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, et al.: Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 2000, 15(1):120-128.